I. Bourdeix

发表

Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner

D. Vervloet, M. Molimard, V. Le Gros, 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

M. Humbert, A. Didier, P. Berger, 2013, Chest.

Nicardipine in the prevention of spasm-induced neurological deficits after subarachnoid hemorrhage: a dose-ranging study.

P. Chaumet‐Riffaud, H. Massiou, I. Bourdeix, 1992, Surgical neurology.

IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study.

M. Dougados, B. Amor, B. Combe, 1992, Arthritis and rheumatism.

Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).

D. Benhamou, A. Cuvelier, J. Muir, 2001, Respiratory medicine.

Formoterol 12 μg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: A multicenter, randomized, open-label, parallel-group study

C. Brambilla, I. Bourdeix, V. L. Gros, 2003 .

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.

M. Molimard, V. Le Gros, I. Bourdeix, 2001, Respiratory medicine.

Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.

M. Molimard, V. Le Gros, I. Bourdeix, 2012, Respiratory medicine.

Effect of omalizumab in health care workers with occupational latex allergy.

V. Le Gros, I. Bourdeix, F. Leynadier, 2004, The Journal of allergy and clinical immunology.

A Randomized-Controlled Trial Of Omalizumab In Patients With Severe Difficult To Control Nonatopic Asthma

M. Humbert, A. Didier, P. Berger, 2012, ATS 2012.

Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting.

M. Molimard, V. Le Gros, I. Bourdeix, 2010, Journal of aerosol medicine and pulmonary drug delivery.

Impact of ELN recommendations in the management of first‐line treated chronic myeloid leukaemia patients: a French cross‐sectional study

P. Cony-Makhoul, M. Tulliez, F. Nicolini, 2016, British journal of haematology.

Effects of switching aromatase inhibitors on arthralgia: the ATOLL study.

D. Spaeth, M. Tubiana, C. Roux, 2009 .

Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

V. Rohmer, P. Caron, S. Dejager, 2005, The Journal of clinical endocrinology and metabolism.

SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.

L. Zelek, Thierry Nguyen, S. Bisot-Locard, 2012, Bulletin du cancer.

Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up

A. Destée, P. Pollak, O. Rascol, 2004, Journal of Neurology, Neurosurgery & Psychiatry.

Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.

M. Molimard, V. Le Gros, I. Bourdeix, 2005, Respiratory medicine.

Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study

C. Bungener, T. Moreau, O. Heinzlef, 2016, European Neurology.

Laval assessing octreotide LAR in inoperable bowel obstruction

L. Zelek, Thierry Nguyen, S. Bisot-Locard, 2012 .

Reply: Brief cognitive tests in the screening of dementia in Parkinson's disease

K. Dujardin, B. Dubois, F. Durif, 2011 .

Cognitive Tests in the Screening of Dementia in Parkinson ’ s Disease

B. Dubois, F. Durif, A. Duhamel, 2011 .

Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma.

M. Humbert, A. Didier, P. Chanez, 2010, Respiratory medicine.

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

M. Sarazin, T. Dantoine, S. Auriacombe, 2005, International journal of clinical practice.

Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

F. Durif, I. Devaux, I. Bourdeix, 2001, European Neurology.

Parkinson's disease dementia can be easily detected in routine clinical practice

K. Dujardin, B. Dubois, F. Durif, 2010, Movement disorders : official journal of the Movement Disorder Society.

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.

G. Remington, J. Azorin, R. Spiegel, 2001, The American journal of psychiatry.

Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?

A. Destée, I. Bourdeix, K. Rérat, 2008, European Neurology.

Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: Interest of the Deco questionnaire

J. Dartigues, I. Bourdeix, L. Carcaillon, 2011, The journal of nutrition, health & aging.

[Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].

P. Barberger‐Gateau, J. Dartigues, I. Bourdeix, 2002, Revue neurologique.

Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner

D. Vervloet, M. Molimard, V. Le Gros, 2010, Journal of Asthma.